Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody... (CD19 and MDX-1342 CD19 is a B-cell sp...)

HOME >> MEDICINE >> TECHNOLOGY

Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342

Date:12/4/2007

CD19 and MDX-1342

CD19 is a B-cell specific membrane protein that is broadly expressed during B-cell development, from the pro-B-cell to the early plasma cell stage.

Clinical studies have demonstrated that depleting monoclonal antibodies directed against CD20, another B-cell specific membrane protein that has a more restricted expression pattern than CD19 during B-cell development, are effective in treating rheumatoid arthritis and various B-cell malignancies, and show promise in treating other inflammatory diseases such as systemic lupus erythematosis and multiple sclerosis.

MDX-1342 is a fully human antibody that binds selectively to CD19 expressed on B-cells (without targeting stem cells or fully differentiated plasma cells, which lack CD19 expression) and induces the depletion and elimination of CD19-positive B-cells.

About Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia (CLL) is a cancer that affects B-cell lymphocytes, an important component of the immune system that helps the body fight infection or cancer. The American Cancer Society estimates that in 2007, approximately 15,340 new cases of chronic lymphocytic leukemia will occur in the United States, and approximately 4,500 people will die of the disease in 2007.

About Rheumatoid Arthritis

According to the American College of Rheumatology, more than two million Americans suffer from rheumatoid arthritis (RA), a chronic autoimmune disease that develops when certain cells of the immune system inappropriately attack healthy joint tissue, thereby causing swelling, inflammation and damage of joints, as well as systemic inflammation and damage of other tissues.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectio
'/>"/>

SOURCE Medarex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study

Post Your Comments:

(Date:12/4/2009)OMAHA, Neb., Dec. 4 Amber Pharmacy announced today that it received accreditation by the Accreditation Commission for Health Care, Inc. (ACHC) for specialized pharmacy services. For nearly 15 years,

(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new d

(Date:12/4/2009)SAN DIEGO, Calif., Dec. 4 Suneva Medical, a privately-held aesthetic medical device company, today announced the appointment of Philip Ranker as Vice President and Chief Financial Officer. In this r

Breaking Medicine Technology:Amber Pharmacy Earns Accreditation From ACHC 2 PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2 PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3 PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4 PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5 Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2 Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3 Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4 New technique can help diagnose mesothelioma 55087 1 New technique can help diagnose mesothelioma 55087 2 Business Association in Denver Invites Award winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using 55085 1 Business Association in Denver Invites Award winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using 55085 2 Business Association in Denver Invites Award winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using 55085 3 Business Association in Denver Invites Award winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using 55085 4 Fragile period of childhood brain development could underlie epilepsy 55082 1 Fragile period of childhood brain development could underlie epilepsy 55082 2

[0] Amber Pharmacy Earns Accreditation From ACHC [0] PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop [0] Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer

...Utilized as an Adjuvant and Play Key Role in the,T...., March 20, 2007 /PRNewswire-FirstCall/ --,Immune...,BioSciences Holdings, Inc. , announced today that...nalog, Homspera, suggests that the,compound has po...,adjuvant. Studies performed in animal models of i...

...ronger FDA says drug review programs need more,mon...ire/ -- A new,estimate by the Alzheimer,s Associat...e living with Alzheimer,s disease -- a 10,percent ...ould more,than triple in the coming decades unless...bilitating illness. , The new numbers re-emphasize...

Other Medicine Technology:ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent 2 ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent 3 ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent 4 Alzheimer's Growth Shows Need for Increased FDA Funding 2 Alzheimer's Growth Shows Need for Increased FDA Funding 3

ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent Alzheimer's Growth Shows Need for Increased FDA Funding

(Date:12/5/2009)AVIVA today announced the launch of International Solutions, an innovative new international private medical insurance plan which follows the acclaimed modular design of its UK equivalent. In addition

(Date:12/4/2009)PALO ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: VAR ) announced today that its Board of Directors has set the regular 2010 Annual Meeting of Stockholders for February 11, 2010 with a record

(Date:12/4/2009)SAN FRANCISCO, Dec. 4 Medithrive, Inc. has won the Patient,s Choice Award as the favorite dispensary in the SF Bay Area by popular vote conducted by the online website, www.weedmaps.com. Despite on

(Date:12/4/2009)SCOTTSDALE, Ariz., Dec. 4 Healthcare Trust of America, Inc. ("HTA"), a self-managed, non-traded, real estate investment trust, announced the execution of a purchase and sale agreement to acquire a th

(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w

Breaking Medicine News(10 mins):Health News:AVIVA's Private Health Insurance Products Solutions Go International 2 Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2 Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2 Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2

[0] AVIVA's Private Health Insurance Products Solutions Go International [0] Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto [0] Medithrive Voted #1 Medicinal Marijuana Dispensary in Bay Area [0] Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana [0] Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist

...ck bowel; warnings not mandated on packages, study...ws) -- Parents need to be better warned about pote...wing toys with magnets before shopping for present...gestive tract, the need for surgery, and even deat...

...rescription Prenatal Vitamins , , PrimaCare O...ensive once-daily prescription prenatal vitamin in...nd EPA , , ST. LOUIS, Dec. 17 KV Pharmaceuti...al vitamins - has enhanced the formulation of one ...

...od of use to treat mildly infected diabetic foot u... double-blinded multi-center clinical trials of pe...ARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) an...ild diabetic foot infection were published in the ...

...swire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ... the global life sciences markets, today reported ...ear-end results for the period ended October 31, 2...Services goodwill that was previously announced on...

...SynCare, LLC, today announced that,Ian Duncan has ...-renowned,author and expert in the field of diseas...ings a wealth of experience and knowledge to the S..."Ian is a pioneer in the use of,risk-adjustment an...

... mPay Gateway, a Minneapolis, MN company specia... today that a Minneapolis-area primary care clinic...ceivable by more than 50% after successfully imple...amatic A/R reduction within 12 weeks. , ...

Magnets in Kids' Toys Pose Broad Dangers KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R)Pexiganan Phase 3 Clinical Trials Results Published in December Issue of CID MDS Reports Preliminary Fourth Quarter 2008 Results SynCare Announces Ian Duncan Joins Board of Directors Use of mPay Gateway Cuts Patient Receivables by 50%

Sapphire Surgical Knife With Titanium Handle

Capsule polisher aka Drysdale Nucleus Manipulator

Capsule polisher

Nucleus Spatula & Knife

Medicine Products:

Sapphire Surgical Knife With Titanium Handle Capsule polisher aka Drysdale Nucleus Manipulator Capsule polisher Nucleus Spatula & Knife

Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody...(CD19 and MDX-1342 CD19 is a B-cell sp...),Health